A promising future

In recent years advances in molecular biology have aided our understanding of the patho-genesis of cancer. This has occurred concurrently with technological advances allowing rational drug design and development (such as tyrosine kinase inhibitors, monoclonal antibodies and anti-sense oligonucleotides). Combining these two advances has been very beneficial in the drug development process such that we now have a wealth of opportunities. The challenge now is how to rationally categorize and prioritize the many strategies that can be deployed. In the discussion below, we propose a rational process to evaluate the merits of different strategies and use prostate cancer as an example. The different strategies include focusing on cytotoxic agents, synthetic lethality strategies, angiogenesis, oncogene addiction pathways and activated survival pathways such as those driven by systems of inflammation and/or metabolism.

0 0

Post a comment